This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Jan 1;140(1):28-29.

doi: 10.1001/jamaophthalmol.2021.4586.

Risk Factors for Intraocular Inflammation After Brolucizumab Treatment

Caroline R Baumal¹

Affiliations

PMID: 34817570
DOI: 10.1001/jamaophthalmol.2021.4586

Risk Factors for Intraocular Inflammation After Brolucizumab Treatment

Caroline R Baumal. JAMA Ophthalmol. 2022.

. 2022 Jan 1;140(1):28-29.

doi: 10.1001/jamaophthalmol.2021.4586.

Author

Caroline R Baumal¹

Affiliation

¹ New England Eye Center, Tufts Medical Center, Boston, Massachusetts.

PMID: 34817570
DOI: 10.1001/jamaophthalmol.2021.4586

No abstract available

PubMed Disclaimer

Comment in

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani AM, Zarbin MA, Barakat MR, Albini TA, Kaiser PK, B G, Agashivala N, Yu JS, Wykoff CC, MacCumber MW. Khanani AM, et al. JAMA Ophthalmol. 2022 Jan 1;140(1):20-28. doi: 10.1001/jamaophthalmol.2021.4585. JAMA Ophthalmol. 2022. PMID: 34817566 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database